Pay in 4 interest-free payments of $7.31 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Novel dual incretin agent, tirzepatide (LY3298176), for the treatment of type 2 diabetes mellitus and cardiometabolic health
In addition to appetite control, semaglutide, and tirzepatide enhance insulin sensitivity and slow gastric emptying, promoting a more stable metabolism
doi: 10.1194/jlr.M051680 10 YangTNianYLinHLiJLinXLiTet al
Retatrutide Half-Life and Pharmacokinetics Retatrutide has a ~6-day half-life achieved through fatty acid albumin binding comparable to semaglutide (~7 days) and tirzepatide (~5 days)
Tirzepatide induced significant improvements in estradiol, testosterone, LH, FSH, and LH/FSH ratio
US$ 27.23
US$ 25.29
US$ 20.11
